Business description: Perrigo Company plc

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.

Number of employees: 8,100

Sales by Activity: Perrigo Company plc

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Consumer Self-Care Americas (Csca)

269.31Cr 292.59Cr 296.23Cr 269.37Cr 258.53Cr

Consumer Self-Care International(Csci)

144.56Cr 152.57Cr 169.33Cr 167.96Cr 166.77Cr

Geographical breakdown of sales: Perrigo Company plc

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States (U.S.)

256.59Cr 287Cr 291.68Cr 264.93Cr 254.01Cr

Europe (Excl. Ireland)

136.93Cr 144.5Cr 158.17Cr 156.5Cr 157.42Cr

All Other Countries

18Cr 11Cr 12Cr 12Cr 9.67Cr

Ireland

2.37Cr 2.93Cr 4.08Cr 3.96Cr 4.21Cr

Executive Committee: Perrigo Company plc

Manager TitleAgeSince
Chief Executive Officer 63 07/06/2026
Director of Finance/CFO 51 16/05/2022
Chief Operating Officer - 23/06/2025
Chief Tech/Sci/R&D Officer 45 06/01/2025
Investor Relations Contact - 01/07/2011

Composition of the Board of Directors: Perrigo Company plc

Director TitleAgeSince
Director/Board Member 75 01/11/2014
Director/Board Member 61 07/11/2016
Director/Board Member 70 06/02/2017
Chairman 57 -
Director/Board Member 63 30/07/2022
Director/Board Member 56 01/11/2023
Director/Board Member 58 15/01/2025
Director/Board Member 60 01/05/2025
Director/Board Member 66 30/06/2026
Director/Board Member 52 30/06/2026

Shareholders: Perrigo Company plc

NameStocks%Valuation
BlackRock Advisors LLC
11.93 %
1,65,01,498 11.93 % 182 M $
T. Rowe Price Associates, Inc. (IM)
10.13 %
1,40,16,148 10.13 % 155 M $
T. Rowe Price International Ltd.
9.668 %
1,33,76,776 9.668 % 148 M $
LB Hercules Holdings LLC
7.56 %
1,04,60,080 7.56 % 116 M $
Vanguard Portfolio Management LLC
5.884 %
81,41,919 5.884 % 90 M $

Company details: Perrigo Company plc

Perrigo Co. Plc

The Sharp Building

2/74, Dublin

+353 1 709 4000

http://www.perrigo.com
address Perrigo Company plc(PRGO)

Group companies: Perrigo Company plc

NameCategory and Sector
Pharmaceuticals: Major
Miscellaneous Commercial Services
Pharmaceuticals: Other
Pharmaceuticals: Major
Financial Conglomerates

Other Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-1.83%-7.26%-62.88%-69.35% 141.41Cr
-2.33%-2.09%+49.88%+170.51% 1,06000Cr
-0.82%-2.30%+63.79%+62.00% 62TCr
-0.73%-4.98%+28.91%+82.99% 44TCr
+0.33%-1.17%+31.07%+27.09% 33TCr
-0.02%-2.85%+29.15%+45.24% 28TCr
-3.89%-11.22%+22.81%+27.30% 27TCr
+0.66%-1.42%-26.59%-37.71% 22TCr
-0.06%-2.88%+23.07%+62.33% 20TCr
-3.72%-1.10%+18.41%+70.56% 16TCr
Average -1.24%-3.65%+17.76%+44.10% 35.75TCr
Weighted average by Cap. -1.32%-2.96%+36.71%+83.85%
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
10.22USD
Average target price
16.50USD
Spread / Average Target
+61.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRGO Stock
  4. Company Perrigo Company plc